Resumo

OSPINA-IDARRAGA, Juan Alejandro et al. Latin American Study Group of Lymphoproliferatives (GELL) for the management of Lymphoma in a state of Pandemic SARS CoV-2 / COVID 19. rev.colomb.cancerol. [online]. 2020, vol.24, suppl.1, pp.192-226.  Epub 08-Maio-2021. ISSN 0123-9015.  https://doi.org/10.35509/01239015.690.

The existence of SARS-CoV2, the cause of COVID 19 disease, was detected for the first time in China in December 2019. The virus quickly spread across Europe and Asia, taking a couple months to reach Latin America. It has been shown that elderly patients and those with chronic diseases, including cancer, have a higher risk of mortality from COVID-19. Consequently, many doubts arise in the group of health professionals responsible for treating patients with cancer during the pandemic, as they must balance the risk-benefit of delivering treatment to patients with an increased risk for severe manifestations resulting from COVID-19. In this consensus we propose recommendations for hematology professionals who provide treatment to patients suffering from some type of lymphoma, with the aim of clarifying the clinical picture during the pandemic.

Palavras-chave : COVID-19; Lymphoma; Treatment.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )